Prostate Cancer

Since I’ve become a patient and advocate, my social media algorithm now mostly shows cancer-related content. Here’s an open letter to said algorithm, or as I call it, “Algo.”

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

With a wink and wearing a mischievous smile, my friend “Charley” likes to relate how he learned about his diagnosis of prostate cancer several years ago.

From comedian Chris Tucker teaming up with a nonprofit to educate Black men on their prostate cancer risk to Leeane Hainby and Rep. Jamie Raskin providing updates on their cancer treatment, here’s what’s happening in the cancer space this week.

The combination demonstrated survival benefit in patients with metastatic hormone-sensitive prostate cancer, regardless of risk or volume of disease.

From Senator Bob Casey undergoing prostate cancer surgery to a man giving away his Superbowl tickets to a good friend with stage 4 cancer, here’s what is happening in the oncology space this week.

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed.

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

Many men — my former self included — can be stubborn when it comes to cancer screenings or visiting the doctor. Thankfully I’ve changed my ways, which saved my life.

An expert on urological side effects of cancer treatments most often associated with prostate cancer discusses options, even for those decades past initial treatment.

A data monitoring committee recommended to stop the phase 3 trial in metastatic hormone-sensitive prostate cancer due to a lack of progression-free survival and overall survival with combination therapy.

Here are four ways I found purpose in my life after being diagnosed with cancer.

From Tennis star Chris Evert’s cancer-free status to Duran Duran’s Andy Taylor talking about his prostate cancer, here’s what’s happening in the oncology space this week.

Compared with CT based radiotherapy, MRI-guided treatment resulted in fewer side effects for patients with prostate cancer.

Poor body composition was associated with increased risk of death in men with localized prostate cancer, according to recent study findings.

A retired psychotherapist and social worker published a memoir detailing his experiences with disease and navigating the health care space, as well as “all the things that people think about (but) they don't necessarily talk about or even talk to their doctors about.”

More than half of patients with low- or intermediate-risk prostate cancer who underwent treatment with Erleada had no evidence of residual disease after 90 days, a recent study showed.

When I was asked to speak to a youth service club about my cancer, they asked some meaningful questions, making me take stock of my experience.

TAVT-45, a drug that can be mixed with juice or water, showed similar efficacy in treating metastatic castration-resistant prostate cancer as Zytiga.

From high prices in the supermarket to rising PSA levels, inflation can affect patients with cancer on more than one level.

From prostate cancer to disease spread in the brain, one patient learned how to recognize how far he has come since his journey began.

From Tina Turner’s son, Ronnie, dying of cancer to the Miami Dolphins honoring a group of people who raised over $5 million for oncology care and research, here is what’s happening in the cancer space this week.

Men with obesity before starting prostate cancer treatment may have an increased risk for death from heart disease or any cause rather than from prostate cancer itself, study results showed.

Although researchers analyzed internet searches of men with prostate cancer, patient-provider communication is still key for education, according to one of the study authors.

A new study may provide hope that future treatments can delay androgen-deprivation therapy and prolong survival in patients with oligometastatic prostate cancer.

When my wife surprised me with a prostate cancer awareness T-shirt, I realized that those small gestures matter the most.

From the singer of “Duran Duran” revealing his stage 4 cancer diagnosis — and missing the band’s induction to the Rock & Roll Hall of Fame because of it — to Barry Corbin’s oral cancer fears, here’s what’s happening in the oncology space this week.

Now that I consider myself as a prostate cancer veteran, I find joy in offering support to others who have fears about their disease and death.

The study investigators will review the efficacy of [Lu-177]-PNT2002, a radioligand treatment, compared with Zytiga or Xtandi in patients with metastatic castration-resistant prostate cancer.